May 13, 2026 7:00 am EDT Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
May 5, 2026 4:05 pm EDT Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 5, 2026 4:01 pm EDT Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
Mar 23, 2026 7:00 am EDT Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
Feb 18, 2026 4:05 pm EST Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Nov 17, 2025 4:30 pm EST Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
